Improving radiation treatment for pediatric cancers using advanced data science
Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science
This study is looking at how the genes of aggressive childhood tumors, like diffuse midline glioma and high-risk neuroblastoma, affect how well radiation therapy works, so we can create better treatments that are more suited to each child's unique cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10931411 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness and precision of radiation therapies for aggressive pediatric tumors, specifically diffuse midline glioma and high-risk neuroblastoma. By collaborating with leading cancer centers, the project aims to understand how the genetic makeup of these tumors influences their response to radiation. The study will analyze tumor samples from children before and after treatment to identify mechanisms of radiation resistance, ultimately aiming to develop more effective treatment strategies. Patients may benefit from improved radiation therapies tailored to their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with diffuse midline glioma or high-risk neuroblastoma.
Not a fit: Patients with other types of cancers or those who are not within the pediatric age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation treatments for children with aggressive cancers, potentially improving survival rates and reducing side effects.
How similar studies have performed: Previous research has shown promise in using advanced data science approaches to improve cancer treatments, indicating potential for success in this novel application.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Haas-Kogan, Daphne a. — Dana-Farber Cancer Inst
- Study coordinator: Haas-Kogan, Daphne a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.